On September 26, 2017, FDA Commissioner Scott Gottlieb, M.D. released a statement about FDA's ramped up regulatory initiatives for drug compounders. These initiatives include: (1) publishing a report that provides a list of all the drugs that outsourcing facilities have compounded; (2) publishing a guide entitled "Outsourcing Facility Information," which is a compilation of key regulatory information applicable to outsourcing facilities; and (3) conducting the sixth intergovernmental meeting on drug compounding allowing intergovernmental agencies to coordinate their regulatory efforts for all compounders. These efforts demonstrate that FDA is continuing to actively oversee the regulation of drug compounding and is looking to work closer with state boards of pharmacy to coordinate its various enforcement initiatives. Drug compounders should continue to closely monitor their compliance with all applicable state and federal regulation and guidance.
For more information on this important topic, please read the full client alert here.
This article is presented for informational purposes only and is not intended to constitute legal advice.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.